DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Temovate E is a drug marketed by Fougera Pharms and is included in one NDA.
The generic ingredient in TEMOVATE E is clobetasol propionate. There are fourteen drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
A generic version of TEMOVATE E was approved as clobetasol propionate by COSETTE on February 16th, 1994.
Recent Clinical Trials for TEMOVATE E
Identify potential brand extensions & 505(b)(2) entrants
|VA Office of Research and Development||N/A|
|University Hospitals Cleveland Medical Center||N/A|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Fougera Pharms||TEMOVATE E||clobetasol propionate||CREAM;TOPICAL||020340-001||Jun 17, 1994||DISCN||Yes||No||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|